Addressing the Medical Need in CLL: How BTK Inhibitors Are Improving Outcomes

Get up to date on optimal use of BTK inhibitors in the care of your patients with CLL with an interactive on-demand Webcast and downloadable slides from a live Webinar, along with expert commentaries and our BTK Inhibitor AE Management Tool.
Ian W. Flinn, MD, PhD

ClinicalThought

In this commentary, Ian W. Flinn, MD, PhD, provides expert answers to frequently asked questions on the use of BTK inhibitors in the management of patients with CLL.

Ian W. Flinn, MD, PhD Released: November 16, 2020
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
BeiGene, Ltd.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue